Jazz Pharmaceuticals (JAZZ) Amortization of Deferred Charges (2010 - 2021)

Jazz Pharmaceuticals' Amortization of Deferred Charges history runs 11 years deep, the most recent figure standing at $15.7 million for Q1 2021.

• In Q1 2021, Amortization of Deferred Charges rose 30.73% year-over-year to $15.7 million; the TTM figure through Mar 2021 stood at $60.3 million (up 27.68% YoY), while the FY2020 annual figure was $56.7 million, up 22.12% from the prior year.
• Amortization of Deferred Charges was $15.7 million for Q1 2021 at Jazz Pharmaceuticals, down from $16.0 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $16.0 million in Q4 2020 to a low of $5.6 million in Q1 2017.
• Historically, Amortization of Deferred Charges has averaged $11.3 million across 5 years, with a median of $11.3 million in 2018.
• Biggest YoY gain for Amortization of Deferred Charges was 89.08% in 2018; the steepest drop was 4.62% in 2018.
• A 5-year view of Amortization of Deferred Charges shows it stood at $10.8 million in 2017, then rose by 4.62% to $11.3 million in 2018, then advanced by 6.11% to $12.0 million in 2019, then soared by 33.93% to $16.0 million in 2020, then retreated by 2.23% to $15.7 million in 2021.
• The last three Amortization of Deferred Charges figures came in at $15.7 million (Q1 2021), $16.0 million (Q4 2020), and $15.8 million (Q3 2020), per Business Quant data.